Recent investigation has focused on identifying signaling pathways that inhibit cardiac hypertrophy, a major risk factor for cardiovascular morbidity and mortality. In this context, nitric oxide (NO), signaling via cGMP and cGMP-dependent protein kinase type I (PKG I), has been recognized as a negative regulator of cardiac myocyte (CM) hypertrophy. However, the underlying mechanisms are poorly understood. Here, we show that PKG I inhibits CM hypertrophy by targeting the calcineurin-NFAT signaling pathway. Calcineurin, a Ca 2؉ -dependent phosphatase, promotes hypertrophy in part by activating NFAT transcription factors which induce expression of hypertrophic genes, including brain natriuretic peptide (BNP). C ardiac hypertrophy has been viewed as a compensatory mechanism of the heart that helps to maintain cardiac output during pathological states with sustained increases in hemodynamic load. However, hypertrophy often heralds decompensation, transition to heart failure, and sudden death (1). To understand the molecular mechanisms of this ultimately maladaptive response, much investigation has focused on the signaling pathways controlling hypertrophy at the level of the single cardiac myocyte (CM). It has emerged that the hypertrophic response is orchestrated by growth factors and cytokines acting through several interdependent signaling cascades, including, for example, specific G protein isoforms, low-molecular-weight GTPases, mitogen-activated protein kinases, and protein kinase C (2, 3). In addition, recent studies have recognized the importance of Ca 2ϩ -sensitive signaling pathways in CM hypertrophy (4). One prominent Ca 2ϩ -dependent pathway involves the Ser͞ Thr protein phosphatase calcineurin. Activation of calcineurin by Ca 2ϩ results in the dephosphorylation and nuclear translocation of cytoplasmic latent nuclear factor of activated T cells (NFAT) transcription factors (5). Many lines of evidence, including the antihypertrophic effects of endogenous calcineurin inhibitory peptides, have contributed to the conclusion that the calcineurin-NFAT pathway plays an essential role in the hypertrophic response to growth factor stimulation (6-9). Importantly, calcineurin activates and interacts with other hypertrophic signaling cascades (10-13), supporting the concept that CM hypertrophy is controlled by crosstalking signaling networks.
C
ardiac hypertrophy has been viewed as a compensatory mechanism of the heart that helps to maintain cardiac output during pathological states with sustained increases in hemodynamic load. However, hypertrophy often heralds decompensation, transition to heart failure, and sudden death (1) . To understand the molecular mechanisms of this ultimately maladaptive response, much investigation has focused on the signaling pathways controlling hypertrophy at the level of the single cardiac myocyte (CM). It has emerged that the hypertrophic response is orchestrated by growth factors and cytokines acting through several interdependent signaling cascades, including, for example, specific G protein isoforms, low-molecular-weight GTPases, mitogen-activated protein kinases, and protein kinase C (2, 3) . In addition, recent studies have recognized the importance of Ca 2ϩ -sensitive signaling pathways in CM hypertrophy (4) . One prominent Ca 2ϩ -dependent pathway involves the Ser͞ Thr protein phosphatase calcineurin. Activation of calcineurin by Ca 2ϩ results in the dephosphorylation and nuclear translocation of cytoplasmic latent nuclear factor of activated T cells (NFAT) transcription factors (5) . Many lines of evidence, including the antihypertrophic effects of endogenous calcineurin inhibitory peptides, have contributed to the conclusion that the calcineurin-NFAT pathway plays an essential role in the hypertrophic response to growth factor stimulation (6) (7) (8) (9) . Importantly, calcineurin activates and interacts with other hypertrophic signaling cascades (10) (11) (12) (13) , supporting the concept that CM hypertrophy is controlled by crosstalking signaling networks.
Adding yet another level of complexity, recent studies have identified signaling pathways opposing CM hypertrophy (14) (15) (16) . In this context, the free radical gas nitric oxide (NO) has been recognized as a negative regulator of the hypertrophic response (17) (18) (19) (20) . Antihypertrophic effects of NO are mediated via the second messenger cGMP and its activation of cGMP-dependent protein kinase type I (PKG I) (19, 21) , although the mechanisms involved have not been elucidated. Specifically, it is not known whether PKG I exerts antihypertrophic effects via an autonomous inhibitory pathway and͞or via suppression of certain hypertrophic signaling cascades. Because PKG I regulates [Ca 2ϩ ] i at multiple levels (22), we postulated that PKG I may suppress hypertrophy via inhibition of Ca 2ϩ -dependent signaling pathways.
In the present study, we demonstrate that NO and cGMP, acting via PKG I, inhibit the hypertrophic calcineurin-NFAT signaling pathway in CM. Our results reveal a complex interplay of the NO-cGMP-PKG I and calcineurin-NFAT signaling cascades and provide a framework for understanding how NO inhibits CM hypertrophy.
Materials and Methods
Materials. The PKG-selective cGMP analog 8-para-chlorophenylthio-cGMP (8-pCPT-cGMP) was purchased from BioLog Life Science Institute (Bremen, Germany), the L-type Ca 2ϩ -channel (LTCC) blocker verapamil and ␣ 1 -adrenoreceptor agonist phenylephrine (PE) from Sigma, and the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) and LTCC agonist BAY K 8644 from Calbiochem.
morning, CM were switched to DMEM͞medium 199 supplemented only with glutamine and antibiotics (maintenance medium). Plasmid Constructs, Transfection, and Luciferase Assay. A calcium phosphate procedure was used to transfect CM with luciferase reporter plasmids driven by three NFAT-binding sites (p3xNFAT-GL), three myocyte enhancer factor-2 (MEF2)-binding sites (p3xMEF2-GL), or by 2,501 bp of the rat brain natriuretic peptide (BNP) gene 5Ј flanking region (pBNP 2501 -GL; refs. 26 and 27) . Luciferase activities were measured by using a Lumat LB 9501 luminometer (Berthold, Nashua, NH).
NFAT3
Immunofluorescence. The nuclear localization of NFAT3 in CM was determined by immunostaining (6) . Antibodies directed against rat NFAT3 are not commercially available; therefore, CM were transfected with an expression plasmid encoding human NFAT3. An antibody against human NFAT3 and an FITC-conjugated secondary antibody were purchased from Santa Cruz Biotechnology and Dianova (Hamburg, Germany), respectively. Transfected CM were scored for nuclear NFAT3 staining.
Measurement of Single LTCC Activity. Patch-clamp experiments were performed in the cell-attached configuration, and single LTCC open probability was calculated as described (28) . Singlechannel currents were elicited for 150 msec at 1.66 Hz by depolarizing pulses from Ϫ100 to ϩ20 mV. Assessment of the Hypertrophic Response. Brain natriuretic peptide mRNA expression was assessed by Northern blotting by using a 344-bp BNP cDNA probe (26) . CM size was determined by planimetry by using phase contrast microscopy and a digital image analyzer (21) .
Statistical Analysis. Data are presented as mean Ϯ SEM. Differences between groups were analyzed by one-way ANOVA followed by Student's t test with Bonferroni correction. A two-tailed P value Ͻ0.05 was considered to indicate statistical significance.
Results
PKG I Inhibits ␣1-Adrenergic Stimulation of NFAT Nuclear Translocation and Transcriptional Activity. To start exploring whether PKG I interferes with the calcineurin-NFAT signal transduction pathway in CM, the subcellular localization of NFAT3 was examined ( Fig. 1 A-C) . ␣ 1 -Adrenergic stimulation with PE, a known activator of calcineurin and cardiac hypertrophy (6) , increased the percentage of CM positive for nuclear NFAT3 staining (Fig.  1B) . The NO donor SNAP or direct activation of PKG I by the PKG-selective cGMP analog 8-pCPT-cGMP suppressed nuclear translocation of NFAT3 in response to PE stimulation (Fig. 1B) . To determine whether reduced nuclear translocation resulted in decreased NFAT transcriptional activity, CM were transfected with a luciferase reporter plasmid driven by three NFAT consensus binding sites. As shown in Fig. 1D , PE increased NFAT transcriptional activity, whereas SNAP or 8-pCPT-cGMP reduced PE-stimulated NFAT activation. To examine PKG I as a potential mediator of NO͞cGMP effects directly, CM were infected with adenoviral vectors expressing wild-type or catalytically inactive PKG I. Adenoviral expression of wild-type PKG I (1 ϫ 10 4 viral particles per cell) augmented the inhibitory effects of SNAP and 8-pCPT-cGMP on nuclear translocation (Fig. 1C ) and transcriptional activity of NFAT (Fig. 1E) , supporting the concept that PKG I is a downstream mediator of these NO͞cGMP effects. By contrast, adenoviral expression of the catalytically inactive PKG I mutant (1 ϫ 10 4 viral particles per cell) did not affect the suppressive effects of NO͞cGMP ( Fig.  1 C and E) . It should be noted that high concentrations of the catalytically inactive PKG I mutant (1 ϫ 10 5 viral particles per cell) reversed the inhibitory effects of NO͞cGMP on NFAT transcriptional activity (not shown), presumably by competing with endogenous PKG I for cGMP (24) . In all subsequent experiments, PKG I adenoviruses were used at a concentration of 1 ϫ 10 4 viral particles per cell.
PKG I Does Not Inhibit NFAT Transcriptional Activity Induced by a
Constitutively Active Calcineurin Mutant. To distinguish whether PKG I inhibition of NFAT activation is upstream or downstream of calcineurin, CM were infected with an adenovirus encoding a constitutively active calcineurin mutant. Expression of the calcineurin mutant significantly enhanced NFAT transcriptional activity ( Fig. 2A) . In contrast to NFAT activation in response to PE treatment ( Fig. 1 D and E) , NFAT activation by the calcineurin mutant (Fig. 2 A and B) was not inhibited by activation of endogenous or adenovirally expressed PKG I by SNAP or 8-pCPT-cGMP. Taken together, the data presented in Figs. 1  and 2 indicate that NO and cGMP signal via PKG I to inhibit NFAT activation in CM by targeting the calcineurin-NFAT pathway upstream of calcineurin. influx via the LTCC. Conversely, the LTCC agonist BAY K 8644 induced NFAT transcriptional activity (Fig.  3A) . BAY K 8644-induced NFAT activation was suppressed by 8-pCPT-cGMP (Fig. 3A) , an effect that was significantly enhanced by adenoviral expression of wild-type but not catalytically inactive PKG I (Fig. 3B) . To assess the effect of PKG I on LTCC activity directly, patch-clamp experiments were performed. Representative single LTCC recordings are presented in Fig. 3 C-H , and the effects of 8-pCPT-cGMP on single LTCC open probability are summarized in Fig. 3K . Activation of endogenous PKG I by 8-pCPT-cGMP suppressed single LTCC open probability in PE-treated CM (Fig. 3 C, D, and K) . This effect was significantly enhanced by adenoviral expression of wild-type (Fig. 3 G, H, and K) but not catalytically inactive ( ] i transient amplitude in PE-treated CM, and the inhibitory effects of endogenous PKG I were significantly enhanced by adenoviral expression of wild-type but not catalytically inactive PKG I.
PKG I Inhibits the Promoter Activity and mRNA Expression of Brain
Natriuretic Peptide. ␣ 1 -Adrenergic stimulation of both the promoter activity and mRNA expression of BNP, a primary response gene that is induced by NFAT-dependent mechanisms in hypertrophied CM (6) , was inhibited by activation of endogenous PKG I with SNAP or 8-pCPT-cGMP (Fig. 4 A and E) . The inhibitory effects were significantly enhanced by adenoviral expression of wild-type PKG I (Fig. 4 B and E) . Similar to PE-stimulation, adenoviral expression of a constitutively active calcineurin mutant stimulated BNP promoter activity and mRNA expression; however, these effects were not significantly suppressed by activation of endogenous PKG I (Fig. 4 C and F) . Remarkably, SNAP and 8-pCPT-cGMP significantly reduced calcineurin-induced BNP promoter activity and mRNA expression in CM overexpressing wild-type PKG I (Fig. 4 D and F) , which is consistent with an inhibitory effect downstream of calcineurin, additional to the upstream site of inhibition concluded from Figs. 1 and 2.
PKG I Activation Reduces Cardiac Myocyte
Size. An increase in CM size is the hallmark of CM hypertrophy. As previously shown by our group (21), activation of endogenous PKG I by SNAP or 8-pCPT-cGMP reduced the ␣ 1 -adrenergic increase in CM size (Fig. 5A) . Adenoviral expression of wild-type but not catalytically inactive PKG I significantly enhanced the inhibitory effects of SNAP and 8-pCPT-cGMP (Fig. 5B ). An increase in CM size also was induced by adenoviral expression of the constitutively active calcineurin mutant (Fig. 5C) . Activation of endogenous PKG I, however, did not reduce CM size in calcineurinoverexpressing CM (Fig. 5C) , which is consistent with PKG I inhibitory effects upstream of calcineurin. By contrast, adenoviral expression and NO͞cGMP activation of wild-type PKG I suppressed calcineurin-induced increases in CM size (Fig. 5D) , further confirming the additional inhibitory effect of overexpressed PKG I downstream of calcineurin. (Fig. 2) , suggesting that overexpressed PKG I can target NFAT-independent pathway(s). Therefore, we investigated whether overexpressed PKG I interferes with calcineurin activation of the transcription factor MEF2. As shown in Fig. 6A , expression of the constitutively active calcineurin mutant enhanced MEF2 transcriptional activity in CM. Activation of endogenous PKG I by SNAP or 8-pCPT-cGMP did not significantly reduce calcineurin-induced MEF2 activation (Fig. 6A) . However, in CM overexpressing wild-type PKG I, SNAP and 8-pCPT-cGMP exerted a significant inhibitory effect on calcineurin-induced MEF2 activation (Fig. 6B) . Discussion NO, signaling via cGMP and PKG I, has been recognized as a suppressor of CM hypertrophy (17-21); however, there has been little elucidation of the molecular mechanisms involved. The present study shows that NO͞cGMP activation of PKG I inhibits the hypertrophic calcineurin-NFAT pathway in CM by targeting critical, Ca 2ϩ -dependent steps upstream of calcineurin. Adenoviral expression of PKG I enhances the inhibition upstream of calcineurin and unmasks an additional blockade downstream of calcineurin.
Blockade of NFAT-Dependent Hypertrophy Signaling Upstream of
Calcineurin. Calcineurin phosphatase activity is critically dependent on intracellular Ca 2ϩ , and our results indicate that inhibitory effects of PKG I upstream of calcineurin are mediated by interfering with Ca 2ϩ entry via the LTCC. The source of intracellular Ca 2ϩ for stimulating calcineurin is somewhat celltype specific (5). In neuronal cells, for example, calcineurin activation is triggered by Ca 2ϩ influx through the LTCC (27) . It has been proposed that calcineurin activation in CM depends on Ca 2ϩ entry via the LTCC as well (8, 9) , and that the LTCC plays a critical role in the regulation of CM hypertrophy after stimulation of G protein-coupled receptors (19, 30, 31) . Consistent with this, our data demonstrate that the LTCC blocker verapamil inhibits ␣ 1 -adrenoreceptor-induced NFAT activation, whereas the LTCC agonist BAY K 8644 induces NFAT transcriptional activity. PKG I has been shown to suppress LTCC current and [Ca 2ϩ ] i transients in CM (28, 32, 33) . In agreement with these studies, single LTCC open probability and [Ca 2ϩ ] i transient amplitude were reduced by endogenous PKG I in our experimental setting, effects that could be enhanced further by adenoviral expression of PKG I. Importantly, NO͞cGMP activation of PKG I suppressed BAY K 8644-induced NFAT activation, providing direct evidence that PKG I inhibits NFAT activation triggered by Ca 2ϩ entry via the LTCC. In vascular smooth muscle cells, PKG I reduces [Ca 2ϩ ] i by several mechanisms, including decreasing Ca 2ϩ release from the endoplasmic reticulum by phosphorylating the Ins(1,4,5)P 3 -receptorassociated PKG I substrate (34) . Although cardiac muscle function, unlike that of smooth muscle, depends more on Ca 2ϩ influx than Ca 2ϩ release from internal stores, it is possible that the LTCC may not be the only target mediating PKG I effects on [Ca 2ϩ ] i and calcineurin-NFAT activation.
Blockade of NFAT-Independent Hypertrophy Signaling Downstream of
Calcineurin. Whereas endogenous PKG I inhibited NFATdependent hypertrophy signaling upstream of calcineurin, overexpressed PKG I not only enhanced inhibition at this site but also exposed another site of inhibition downstream of calcineurin which was independent of NFAT. Both endogenous PKG I and adenovirally expressed PKG I could inhibit PE activation of NFAT, but neither could inhibit NFAT activation after expres- -independent, constitutively active calcineurin mutant. However, adenovirally expressed PKG I inhibited other indicators of hypertrophy elicited by constitutively active calcineurin, such as BNP transcription and expression and CM size, suggesting that adenovirally expressed PKG I inhibits NFATindependent steps downstream of calcineurin. Importantly, adenoviral expression of a point-mutated, catalytically inactive form of PKG I did not promote antihypertrophic effects downstream of calcineurin. Therefore, spurious effects possibly related to the overexpression of a foreign protein are very unlikely. Calcineurin activates protein kinase C, c-Jun NH 2 -terminal kinase, and the transcription factor MEF2 in CM, indicating that hypertrophic effects of calcineurin are not exclusively mediated by NFAT (10, 11) . In our system, expression of constitutively active calcineurin induced transcription from an MEF2-luciferase reporter plasmid, an effect that was significantly reduced by activation of overexpressed but not endogenous PKG I. Because MEF2 controls the expression of a number of hypertrophy-associated genes, including BNP (35), PKG I inhibitory effects downstream of calcineurin may relate, at least in part, to an inhibition of MEF2 activation.
Antihypertrophic Signaling of NO-cGMP-PKG I via Inhibition of
Calcineurin-NFAT. Although no signal transduction cascade regulates hypertrophy in isolation, a single pathway that operates as an integral part of crosstalking networks can have far-reaching effects (2, 3) . Such an integrated model of hypertrophic signaling predicts that specific inhibition of one central regulatory pathway will diminish activation of other interdependent pathways and will suffice to inhibit the hypertrophic response. Previous studies have shown that pharmacological (6, 10) or genetic (9, 14) inhibition of the calcineurin-NFAT pathway effectively blocks agonist-induced CM hypertrophy, suggesting that PKG I inhibition of calcineurin-NFAT signaling could serve as a central mechanism of the antihypertrophic effects of NO͞cGMP in CM. In vascular smooth cells and other cell types, PKG I inhibits signaling via low-molecular-weight GTPases Ras (36) and RhoA (37) , mediators which have also been implicated in the regulation of CM hypertrophy. It is feasible that PKG I inhibition of such additional signaling pathways also could promote NO͞cGMP antihypertrophic effects in CM. It is noteworthy that NO and cGMP, signaling via PKG I, also suppressed basal NFATtranscriptional activity and BNP-promoter activity in CM (not shown), suggesting that the NO-cGMP-PKG I pathway can modulate gene transcription in nonhypertrophied CM via inhibition of calcineurin-NFAT signaling.
The calcineurin-NFAT signaling cascade is a potent inducer of CM hypertrophy. Thus, cellular defenses involving counterregulatory pathways such as calcineurin-inhibitory peptides (9, 38) and kinases that promote the nuclear export of NFAT (14) are clearly very important. As shown here, the NO-cGMP-PKG I pathway constitutes an additional and distinct mechanism to suppress calcineurin-NFAT hypertrophy signaling in CM.
